tetano
Editor, Senior Moderator
iScience
. 2021 Aug 26;103037.
doi: 10.1016/j.isci.2021.103037. Online ahead of print.
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
Xingyue An[SUP] 1 [/SUP], Melisa Martinez-Paniagua[SUP] 1 [/SUP], Ali Rezvan[SUP] 1 [/SUP], Samiur Rahman Sefat[SUP] 1 [/SUP], Mohsen Fathi[SUP] 1 [/SUP], Shailbala Singh[SUP] 2 [/SUP], Sujit Biswas[SUP] 3 [/SUP], Melissa Pourpak[SUP] 4 [/SUP], Cassian Yee[SUP] 2 [/SUP], Xinli Liu[SUP] 3 [/SUP], Navin Varadarajan[SUP] 1 [/SUP]
Affiliations
Abstract
Despite remarkable progress in the development and authorization of vaccines against SARS-CoV-2, there is a need to validate vaccine platforms for broader application. The current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity in the nasal compartment, which is the first barrier that SARS-CoV-2 virus breaches before dissemination to the lung. We report the development of an intranasal subunit vaccine that uses lyophilized spike protein and liposomal STING agonist as an adjuvant. This vaccine induces systemic neutralizing antibodies, IgA in the lung and nasal compartments, and T-cell responses in the lung of mice. Single-cell RNA-sequencing confirmed the coordinated activation of T/ B cell responses in a germinal center-like manner within the nasal-associated lymphoid tissues, confirming its role as an inductive site to enable durable immunity. The ability to elicit immunity in the respiratory tract can prevent the establishment of infection in individuals and prevent disease transmission.
Keywords: STING; coronavirus; liposomes; nanoparticles; vaccine.
. 2021 Aug 26;103037.
doi: 10.1016/j.isci.2021.103037. Online ahead of print.
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
Xingyue An[SUP] 1 [/SUP], Melisa Martinez-Paniagua[SUP] 1 [/SUP], Ali Rezvan[SUP] 1 [/SUP], Samiur Rahman Sefat[SUP] 1 [/SUP], Mohsen Fathi[SUP] 1 [/SUP], Shailbala Singh[SUP] 2 [/SUP], Sujit Biswas[SUP] 3 [/SUP], Melissa Pourpak[SUP] 4 [/SUP], Cassian Yee[SUP] 2 [/SUP], Xinli Liu[SUP] 3 [/SUP], Navin Varadarajan[SUP] 1 [/SUP]
Affiliations
- PMID: 34462731
- PMCID: PMC8388188
- DOI: 10.1016/j.isci.2021.103037
Abstract
Despite remarkable progress in the development and authorization of vaccines against SARS-CoV-2, there is a need to validate vaccine platforms for broader application. The current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity in the nasal compartment, which is the first barrier that SARS-CoV-2 virus breaches before dissemination to the lung. We report the development of an intranasal subunit vaccine that uses lyophilized spike protein and liposomal STING agonist as an adjuvant. This vaccine induces systemic neutralizing antibodies, IgA in the lung and nasal compartments, and T-cell responses in the lung of mice. Single-cell RNA-sequencing confirmed the coordinated activation of T/ B cell responses in a germinal center-like manner within the nasal-associated lymphoid tissues, confirming its role as an inductive site to enable durable immunity. The ability to elicit immunity in the respiratory tract can prevent the establishment of infection in individuals and prevent disease transmission.
Keywords: STING; coronavirus; liposomes; nanoparticles; vaccine.